Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Phillip H. Lam"'
Autor:
Charity J. Morgan, Hans Moore, Markus S. Anker, Cherinne Arundel, Prakash Deedwania, Richard M. Allman, Samuel Wopperer, Steven N. Singh, Charles Faselis, Gregg C. Fonarow, Qing Zeng, Phillip H. Lam, Lakshmi Tummala, Pamela Karasik, Ali Ahmed
Publikováno v:
The American Journal of Medicine. 133:1460-1470
Background Digoxin reduces the risk of heart failure hospitalization but has no effect on mortality in patients with heart failure without atrial fibrillation in the randomized controlled trial setting. Observational studies of digoxin use in patient
Autor:
Cherinne Arundel, Milton Packer, Steven N. Singh, Yan Cheng, Wayne C. Levy, Richard M. Allman, Vijaywant Brar, Wen-Chih Wu, Gregg C. Fonarow, Phillip H. Lam, Michael R. Zile, Ali Ahmed, Gauravpal S. Gill
Publikováno v:
The American Journal of Medicine. 133:1187-1194
Background Digoxin reduces the risk of heart failure hospitalization in patients with heart failure with reduced ejection fraction. Less is known about this association in patients with heart failure with preserved ejection fraction (HFpEF), the exam
Autor:
Cherinne Arundel, Wilbert S. Aronow, Helen Sheriff, Ali Ahmed, Gregg C. Fonarow, Richard M. Allman, Finn Waagstein, Poonam Bhyan, Phillip H. Lam, Charity J. Morgan, Daniel J. Dooley, Selma F. Mohammed
Publikováno v:
Clinical Cardiology. 41:406-412
BACKGROUND: Digoxin use has been associated with a lower risk of 30‐day all‐cause admission and readmission in patients with heart failure and reduced ejection fraction (HFrEF). HYPOTHESIS: Digoxin use will be associated with improved outcomes in
Autor:
Gregg C. Fonarow, Essraa Bayoumi, Steven N. Singh, Ioannis Kanonidis, Richard M. Allman, Phillip H. Lam, Charity J. Morgan, Awais Malik, Milton Packer, Ahmed Abdelmawgoud, Syed Z. Qamer, Ali Ahmed
Publikováno v:
The American journal of medicine. 132(11)
Background Heart failure is a leading cause for hospital readmission. Digoxin use may lower this risk in patients with heart failure with reduced ejection fraction (HFrEF), but data on contemporary patients receiving other evidence-based therapies ar
Autor:
Ali Ahmed, Lakshmi Tummala, Steven Singh, Gregg C. Fonarow, Lowell Safren, Markus S. Anker, Samuel Wopperer, Phillip H. Lam
Publikováno v:
Journal of the American College of Cardiology. 75:766
Several studies examined the association between digoxin use and outcomes in patients with atrial fibrillation (AF). However, less is known about this association in patients with heart failure (HF) with AF, the examination of which was the objective
Autor:
Hans Moore, Gregg C. Fonarow, Steven N. Singh, Ravi Masson, Phillip H. Lam, Cherinne Arundel, Prakash Deedwania, Awais Malik, Ali Ahmed, Richard M. Allman
Publikováno v:
Journal of the American College of Cardiology. 75:971
Poor outcomes associated with digoxin discontinuation have been shown to be significantly worse in the subgroup of patients with HFrEF not receiving (vs receiving) beta-blockers (p for interaction, 0.044; PMID: 31370952). We examined this association
Autor:
Phillip H. Lam, Daniel J. Dooley, Cherinne Arundel, Michelle White, Bertram Pitt, Wilbert S. Aronow, Javed Butler, Prakash Deedwania, Marc R. Blackman, Gregg Fonarow, Apostolos Tsimploulis, Aliy Ahmed, Charity J. Morgan, Wen-Chih Wu, Poonam Bhyan, Deepak L. Bhatt, Ioannis Kanonidis
Publikováno v:
Journal of the American College of Cardiology. 69:911
Background: In the DIG trial, 6800 patients with HFrEF (EF≤45%) were randomized to receive either placebo (n=3403) or digoxin (n=3397) and followed for a mean of 37 months. Digoxin significantly reduced the risk of HFH by 28% (HR, 0.72; 95% CI, 0.6